Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer
These findings suggest that ARID1A mutations are critical biomarkers for osimertinib resistance and highlight WEE1 inhibition as a promising therapeutic approach for ARID1A-mutant osimertinib-resistant NSCLC.
Authors
- Trever G. Bivona (ORCID: https://orcid.org/0000-0001-5734-4128)
- Collin M. Blakely (ORCID: https://orcid.org/0000-0001-8134-3651)
- Akihiro Nishiyama (ORCID: https://orcid.org/0000-0002-4805-9787)
- Sharon Wesley Dev Sahadevan
- Seiji Yano (ORCID: https://orcid.org/0000-0002-6151-2988)
- Tyiesha Brown (ORCID: https://orcid.org/0000-0003-3456-9417)
- Koji Fukuda (ORCID: https://orcid.org/0000-0001-8544-6244)
- Hiroshi Kotani
- Hiroaki Taniguchi (ORCID: https://orcid.org/0000-0003-0494-5290)
- Hiroyuki Sakaguchi
- Koushiro Ohtsubo (ORCID: https://orcid.org/0000-0002-4490-4306)
- Shinji Takeuchi
- Turja Chakrabarti (ORCID: https://orcid.org/0000-0002-2966-3102)
- Shigeki Nanjo
- Sachiko Arai
- Shigeki Sato (ORCID: https://orcid.org/0009-0001-7753-4559)
Institutions
- Kanazawa University (JP)
- University of California, San Francisco (US)
- Kanazawa University Hospital (JP)
- Life Science Institute (JP)
- Chan Zuckerberg Initiative (United States) (US)
Publication Details
- Journal
- Journal of Thoracic Oncology
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1016/j.jtho.2025.06.007
- Citations
- 7
- Primary Topic
- Chromatin Remodeling and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 5.64
Funders
- Japan Society for the Promotion of Science
- National Cancer Institute